Peer-influenced content. Sources you trust. No registration required. This is HCN.
MDLinx
Invasive mucinous adenocarcinoma carries elevated NRG1 fusion burden that standard DNA-based sequencing reliably misses, while an FDA-approved targeted therapy now exists for confirmed cases.
Hematology/Oncology May 12th 2026
Cancer Therapy Advisor
“Patients with stage IB-IIIA or IIB disease should be considered for neoadjuvant and/or adjuvant systemic therapy based on biomarker testing for PD-L1 status, EGFR mutations, and ALK gene fusions.” — NCCN NSCLC Guidelines, Version 3, 2026
Oncology, Medical February 17th 2026
Hematology Advisor
Final analysis confirms venetoclax plus modified intensive chemotherapy achieves durable remissions with 17.9-month treatment-free intervals in fit elderly AML patients, particularly those with de novo disease.
Clinical Pharmacology July 22nd 2025
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS